Akoustis Technologies Inc expected to post a loss of 17 cents a share - Earnings Preview

Aktis Oncology

04/09/2023 13:36

* Akoustis Technologies Inc  AKTS.OQ   AKTS.O  is expected
to show
a rise in quarterly revenue when it reports  results on
September 6. 
    * The Huntersville North Carolina-based  company is expected
to
report  a 62.2% increase in revenue to $8.439 million from $5.2
million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Akoustis
Technologies Inc
is for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Akoustis
Technologies Inc is $6​, above​ its last closing price of $1.52.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.20       -0.19      -0.20     Missed  -4.2
 Dec. 31 2023  -0.25       -0.25      -0.19     Beat    24
 Sep. 30 2022  -0.22       -0.20      -0.28     Missed  -38.3​
 Jun. 30 2022              -0.19      -0.26     Missed  -34.5
 ​​Mar.        -0.23       -0.22      -0.22     Met     0
 31 2022                                                
 Dec. 31 2021  -0.22       -0.20      -0.23     Missed  -12.2​
 Sep. 30 2021  -0.20       -0.20      -0.25     Missed  -27.1
 Jun. 30 2021  -0.21       -0.19      -0.23     Missed  -23.2
 This summary was machine generated September 4 at 12:36 GMT. 
All figures in US dollars  unless otherwise stated